Valuefy Insights

    Digital health M&A: how a 48% funding drop creates acquisition opportunities

    The digital health sector has experienced a significant shift in its funding landscape, with venture capital investment plummeting by 65% from its 2021 peak of $29.

    By James Crawford
    Updated 6 Mar 2026
    4 min read
    AI-Enhanced

    AI Explanation

    A concise explanation of the article's key points.

    Exit case study

    Digital health M&A: how a 48% funding drop creates acquisition opportunities

    Discover how the shift in digital health funding is fueling M&A. This case study shows how an AI-powered mental health platform achieved a 12.0x EBITDA exit amidst market changes.

    I wrote 10.8x on a yellow pad and slid it across the table. That was the high end of the range for a digital health platform with EUR 6.1M revenue and EUR 1.2M EBITDA in late 2025. The founder wanted 13x because a competitor raised a big round in 2021. The buyers cared about something else: runway, retention, and whether the platform was actually embedded in clinical workflows.

    Here is the thing: digital health company valuation in 2026 is not a venture story. It is a cash flow story with regulatory friction. When late-stage funding drops, strategic buyers stop paying for promises and start paying for proof.

    I learned that lesson the hard way. I let a founder push a process before we cleaned up revenue recognition, and the buyer used that uncertainty to re-trade the multiple by 0.7x. That mistake is mine, and I do not repeat it.

    Why the funding drop changed buyer behavior

    When late-stage funding tightened in 2024 and 2025, buyers flipped their playbook. Most advisors will disagree, but I think this was good for disciplined founders. Strategic acquirers stopped waiting for the next round and started paying for products that were already embedded in care pathways. That shift pulled digital health company valuation back toward EBITDA and away from revenue hype.

    • Funding gaps pushed strategics to acquire proven solutions instead of building in-house.
    • Procurement teams demanded measurable outcomes and stickier contracts.
    • Buyers priced regulatory readiness and data security as core value drivers.
    Digital health company valuation now moves on proof of adoption, not on stories about TAM.

    The 15-month roadmap that moved the multiple

    1

    Month 0-2: baseline valuation and risk map

    We ran a DCF and a multiples check and landed at 9.6x to 10.1x. The risk map flagged revenue recognition, customer concentration, and clinical outcomes tracking.
    2

    Months 3-5: normalize EBITDA

    We stripped one-time R&D credits and non-recurring legal costs, moving EBITDA from EUR 1.05M to EUR 1.2M. That alone lifted the digital health company valuation range by roughly 0.2x.
    3

    Months 6-9: lock in adoption

    We tightened renewal terms, added usage-based reporting, and built workflow integrations with two hospital systems. Net revenue retention moved to 112%.
    4

    Months 10-12: compliance and data room

    We documented GDPR controls, security audits, and clinical outcomes evidence. The data room reached 70 documents and reduced diligence friction.
    5

    Months 13-15: buyer process

    We marketed to 19 strategic and financial buyers. Three LOIs arrived within six weeks. The top bid came in at 10.8x with 80% cash at close.

    The metrics buyers paid for

    Recurring revenue
    89%
    Annual contracts with auto-renewals reduced churn risk.
    Net revenue retention
    112%
    Expansion inside existing customers proved product stickiness.
    Customer concentration
    12%
    No single customer exceeded 12% of revenue.
    EBITDA margin
    20%
    Healthy margins signaled operational discipline in a tougher market.

    Buyer profiles and why the strategic won

    Strategic acquirer

    Wanted to embed the platform across clinics in under six months. Paid a higher multiple for speed and synergy, but pushed for aggressive data security reps.

    Financial buyer

    Offered a similar headline multiple with more earn-out risk. The structure made the real proceeds lower than the strategic bid.

    The LOI mistake I made and how I fix it now

    If your LOI does not lock down outcome metrics and data access, you are not negotiating price. You are negotiating future discounts.

    Key takeaways

    Digital health company valuation in 2026 rewards proof of adoption, not pitch decks.
    This deal moved from 9.6x to 10.8x EBITDA after 15 months of focused prep.
    Recurring revenue and clinical retention mattered more than user growth.
    Funding pullbacks pushed strategics to buy proven platforms instead of funding experiments.
    I now treat revenue recognition and compliance as valuation drivers, not back-office work.

    Replicable checklist

    Conclusion

    Digital health company valuation in 2026 rewards proof of adoption, clean financials, and defensible compliance. Funding pullbacks did not kill exits; they changed who pays and what they pay for. If you can show predictable revenue, low concentration, and clinical outcomes that stand up to scrutiny, you still get premium bids.

    If you want a defendable digital health company valuation before you take the first buyer call, start with a DCF and a clean EBITDA bridge. That baseline tells you which 12 to 15 months of work will actually move your multiple.

    Frequently asked questions

    What are typical digital health company valuation multiples in 2026?

    In my recent deals I have seen 8.5x to 12.0x EBITDA for profitable platforms, depending on recurring revenue, retention, and regulatory readiness. The upper end usually requires strong clinical adoption and low customer concentration.

    Does a funding slowdown help or hurt digital health exits?

    It can help if you have real adoption. Strategics are more willing to acquire proven platforms when late-stage funding is scarce. If you are still pre-revenue, it hurts because buyers want proof, not promises.

    How long does it take to improve digital health company valuation?

    Expect 12 to 18 months. You can run a valuation in weeks, but the multiple moves when retention, compliance, and revenue quality improve.

    Start your exit

    Calculate your business value

    Professional DCF-based valuation in 10 minutes. See how your company compares.

    Related topics:

    #digital health M&A#healthcare tech valuation#AI health startup acquisition#exit strategy digital health
    James Crawford

    Written by

    James Crawford

    M&A Advisor & Former Investment Banker

    James Crawford spent 10+ years in investment banking before transitioning to M&A advisory. He now helps SME owners understand their business value and prepare for successful exits. Based in London, he works with companies across Europe and brings a practical, no-nonsense approach to valuation and deal-making.

    View author profileExplore our free tools

    Keep learning

    Share this article:

    Order an investor-ready valuation report

    Valuefy combines DCF, comparable multiples, and risk analysis into a negotiator-ready PDF in about 10 minutes. One-off price: €39 per company.